PTN Description — Palatin Technologies Inc
Palatin Technologies is a biopharmaceutical company developing medicines based on molecules that modulate the activity of the melanocortin receptor systems. Co.'s product candidates are targeted, receptor-specific therapeutics for the treatment of diseases with unmet medical need and commercial potential. Co.'s U.S. Food and Drug Administration approved melanocortin receptor agonist, Vyleesi®, is an as needed therapy used in anticipation of sexual activity and self-administered in the thigh or abdomen via a single-use subcutaneous auto-injector by premenopausal women with hypoactive sexual desire disorder.
|
|
Free PTN Email Alerts: Get Dividend Alerts Get SEC Filing Alerts |
Strong Buy (4.00 out of 4) 82nd percentile
(ranked higher than approx. 82% of all stocks covered)
Based on data provided by Zacks Investment Research via Quandl.com |
|